ACADIA (ACAD) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
Chief Executive Officer — Catherine Owen Adams Chief Commercial Officer — Thomas Garner Executive Vice President, Head of Research and Development — Elizabeth Thompson, PhD Chief Financial Officer — Mark C. Schneyer Full Conference Call Transcript Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks, followed by Thomas Garner, our Chief Commercial Officer, who will discuss our commercial brands, DAYBUE and NUPLAZID. Also joining us today is Elizabeth Thompson, PhD, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs, and Mark C. Schneyer, our Chief Financial Officer, who will review the financial highlights. Catherine will then provide some closing thoughts before we open up the call to your questions. We are using supplemental slides, available on our website under the Events and Presentations section. On today's call, both GAAP and non-GAAP financial measures will be discusse
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- ACADIA Pharmaceuticals (ACAD) had its price target raised by TD Cowen from $35.00 to $37.00. They now have a "buy" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (ACAD) had its price target lowered by Royal Bank Of Canada from $31.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (ACAD) had its price target raised by Citizens Jmp from $34.00 to $35.00. They now have a "market outperform" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (ACAD) had its price target lowered by Stifel Nicolaus from $25.00 to $24.00. They now have a "hold" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 2/25/26 - Beat
ACAD
Sec Filings
- 2/26/26 - Form SCHEDULE
- 2/26/26 - Form 10-K
- 2/25/26 - Form 8-K
- ACAD's page on the SEC website